SS
PLX icon

SBI Securities’s Protalix BioTherapeutics PLX Stock Holding History

SBI Securities’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2 Hold
1
– – ﹤0.01% 4036
2026
Q1 		$2 Hold
1
– – ﹤0.01% 3965
2025
Q4 		$2 Sell
1
-200
-100% -$409 ﹤0.01% 3974
2025
Q3 		$446 Buy
201
+1
+0.5% +$2 ﹤0.01% 3018
2025
Q2 		$296 Buy
200
+150
+300% +$307 ﹤0.01% 3181
2025
Q1 		$128 Buy
+50
New +$119 ﹤0.01% 3370

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

SBI Securities's PLX Position: Q2 2026 in Review

SBI Securities held its Protalix BioTherapeutics (PLX) position steady in Q2 2026 at 1 share worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #4036.

SBI Securities first reported a position in PLX in Q1 2025 and has held it in 6 quarters since. The position peaked at $446 in Q3 2025. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • SBI Securities held 1 share of Protalix BioTherapeutics worth $2 as of Q2 2026.
  • SBI Securities left its Protalix BioTherapeutics share count unchanged in Q2 2026.
  • Protalix BioTherapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #4036 holding.
  • SBI Securities first reported a position in Protalix BioTherapeutics in Q1 2025 and has held it in 6 quarters since.
  • SBI Securities's Protalix BioTherapeutics position peaked at $446 in Q3 2025.
  • 102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.